Prevention of Rebleeding from Esophageal Varices in Patients with Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy

Gastroenterology

Volumn 149, Issue 3, 2015, Pages 660e1-668.e1

  Sauerbruch, Tilman ^a   Mengel, Martin ^a   Dollinger, Matthias ^b,c   Zipprich, Alexander ^c   Rössle, Martin ^d   Panther, Elisabeth ^d   Wiest, Reiner ^e,f   Caca, Karel ^g   Hoffmeister, Albrecht ^h   Lutz, Holger ⁱ   Schoo, Rüdiger ^j   Lorenzen, Henning ^a   Trebicka, Jonel ^a   Appenrodt, Beate ^a,k   Schepke, Michael ^a,l   Fimmers, Rolf ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

^g KLINIKUM LUDWIGSBURG   (Germany)

^h UNIVERSITY OF LEIPZIG   (Germany)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k SAARLAND UNIVERSITY   (Germany)

^l Heart Center Siegburg   (Germany)

more..

Author keywords

Advanced Liver Disease; HVPG; Nonselective Blocker; TIPS

Indexed keywords

ISOSORBIDE MONONITRATE; PROPRANOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE DINITRATE; NITRIC OXIDE DONOR; VASODILATOR AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEALTH SURVEY; HEMODYNAMICS; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DEVICES; DRUG EFFECTS; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; GERMANY; KAPLAN MEIER METHOD; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RECURRENT DISEASE; STENT; TIME FACTOR; TREATMENT OUTCOME; VENOUS PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERMANY; HUMANS; ISOSORBIDE DINITRATE; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROPRANOLOL; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; QUALITY OF LIFE; RECURRENCE; STENTS; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VENOUS PRESSURE;

EID: 84939833201     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.05.011     Document Type: Article

References (40)

1. M. Sato, R. Tateishi, H. Yasunaga, and et al. Variceal hemorrhage: analysis of 9987 cases from a Japanese nationwide database Hepatol Res 45 2015 288 293
2. V. Jairath, S. Rehal, R. Logan, and et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit Dig Liver Dis 46 2014 419 426
3. T. Sauerbruch, H. Ansari, R. Wotzka, and et al. [Prognostic parameters in liver cirrhosis, varicose bleeding and sclerosing therapy. Prospective comparison of a prognostic system with the Child classification obtained by discriminant analysis] Dtsch Med Wochenschr 113 1988 11 14
4. M. Schepke, G. Kleber, D. Nurnberg, and et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis Hepatology 40 2004 65 72
5. B. Bernard, D. Lebrec, P. Mathurin, and et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis Hepatology 25 1997 63 70
6. L.L. Gluud, E. Langholz, and A. Krag Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Aliment Pharmacol Ther 32 2010 859 871
7. A. Puente, V. Hernandez-Gea, I. Graupera, and et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review Liver Int 34 2014 823 833
8. R. Gonzalez, J. Zamora, J. Gomez-Camarero, and et al. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis Ann Intern Med 149 2008 109 122
9. L. Li, C. Yu, and Y. Li Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis Can J Gastroenterol 25 2011 147 155
10. A.K. Burroughs, and M. Vangeli Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis Scand J Gastroenterol 37 2002 249 252
11. S. Khan, C. Tudur Smith, P. Williamson, and et al. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis Cochrane Database Syst Rev 4 2006 CD000553
12. J.C. Garcia-Pagan, K. Caca, C. Bureau, and et al. Early use of TIPS in patients with cirrhosis and variceal bleeding N Engl J Med 362 2010 2370 2379
13. R. de Franchis Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 43 2005 167 176
14. R. de Franchis Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
15. J. Bosch, J.G. Abraldes, A. Berzigotti, and et al. The clinical use of HVPG measurements in chronic liver disease Nat Rev Gastroenterol Hepatol 6 2009 573 582
16. D.R. Abraczinskas, R. Ookubo, N.D. Grace, and et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 34 2001 1096 1102
17. J. Bosch, and J.C. Garcia-Pagan Prevention of variceal rebleeding Lancet 361 2003 952 954
18. F. Feu, J.C. Garcia-Pagan, J. Bosch, and et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis Lancet 346 1995 1056 1059
19. G. D'Amico, J.C. Garcia-Pagan, A. Luca, and et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review Gastroenterology 131 2006 1611 1624
20. A. Monescillo, F. Martinez-Lagares, L. Ruiz-del-Arbol, and et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding Hepatology 40 2004 793 801
21. A. Escorsell, R. Banares, J.C. Garcia-Pagan, and et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial Hepatology 35 2002 385 392
22. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson, and et al. Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
23. R.J. Groszmann, and S. Wongcharatrawee The hepatic venous pressure gradient: anything worth doing should be done right Hepatology 39 2004 280 282
24. R. de Franchis Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension J Hepatol 33 2000 846 852
25. J.E. Ware, M. Kosinski, and S.D. Keller SF-36 Physical and mental health summary scales: a user's manual 1994 The Health Institute Boston, MA
26. J. Vorobioff, R.J. Groszmann, E. Picabea, and et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study Gastroenterology 111 1996 701 709
27. U. Thalheimer, M. Mela, D. Patch, and et al. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence Gut 53 2004 143 148
28. W.D. Dupont, and W.D. Plummer Jr. Power and sample size calculations. A review and computer program Control Clin Trials 11 1990 116 128
29. J.E. Ware Jr., B. Gandek, M. Kosinski, and et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment J Clin Epidemiol 51 1998 1167 1170
30. E. Sinagra, G. Perricone, M. D'Amico, and et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis Aliment Pharmacol Ther 39 2014 557 568
31. T. Reiberger, G. Ulbrich, A. Ferlitsch, and et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol Gut 62 2013 1634 1641
32. V. La Mura, J.G. Abraldes, S. Raffa, and et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension J Hepatol 51 2009 279 287
33. C. Villanueva, C. Aracil, A. Colomo, and et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding Gastroenterology 137 2009 119 128
34. T. Serste, C. Melot, C. Francoz, and et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites Hepatology 52 2011 1017 1022
35. A. Krag, S. Moller, A.K. Burroughs, and et al. Betablockers induce cardiac chronotropic incompetence J Hepatol 56 2012 298 299
36. P.S. Ge, and B.A. Runyon When should the beta-blocker window in cirrhosis close? Gastroenterology 146 2014 1597 1599
37. E.A. Tsochatzis, J. Bosch, and A.K. Burroughs New therapeutic paradigm for patients with cirrhosis Hepatology 56 2012 1983 1992
38. D. Patch, A. Armonis, C. Sabin, and et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding Gut 44 1999 264 269
39. O. Riggio, L. Ridola, S. Angeloni, and et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial J Hepatol 53 2010 267 272
40. D.Y. Graham, and J.L. Smith The course of patients after variceal hemorrhage Gastroenterology 80 1981 800 809